期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 365, 期 18, 页码 1663-1672出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1105185
关键词
-
资金
- Vertex Pharmaceuticals
- National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton
- Harefield National Health Service Foundation Trust
- Imperial College London
- Cystic Fibrosis Foundation Therapeutic Development Center
- Institute for Translational Health Sciences
- National Center for Research Resources of the National Institutes of Health (NIH) [UL1 RR025014, UL1 RR024153, UL1 RR 025005]
- Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center
- Clinical Translational Research Center [UL1-RR-024134]
- NIH [UL1 RR024989, P30 DK27651, UL1 RR 025758, K23 DK075788, 5UL1 RR025777, 1UL1 RR025744]
- Northern Ireland Clinical Research Network (Respiratory Medicine)
- [VX08-770-102]
Background Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis. Methods We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation. Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 hours (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 weeks. The primary end point was the estimated mean change from baseline through week 24 in the percent of predicted forced expiratory volume in 1 second (FEV1). Results The change from baseline through week 24 in the percent of predicted FEV1 was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P < 0.001). Effects on pulmonary function were noted by 2 weeks, and a significant treatment effect was maintained through week 48. Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P < 0.001). In addition, through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher numbers indicating a lower effect of symptoms on the patient's quality of life) (P < 0.001). By 48 weeks, patients treated with ivacaftor had gained, on average, 2.7 kg more weight than had patients receiving placebo (P < 0.001). The change from baseline through week 48 in the concentration of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per liter (P < 0.001). The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%). Conclusions Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks. Substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride. (Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据